Additional file 12: Figure S9.
Receiver-operating-characteristic (ROC) curves to assess the ability of pretreatment C-X-C motif chemokine 13 (CXCL13) and soluble intercellular adhesion molecule 1 (sICAM1) to differentiate for clinical response in the ADalimumab ACTemrA (ADACTA) trial biomarker population. ROC curves were generated for sICAM1 versus achievement of an American College of Rheumatology (ACR)50 response at week 24 for adalimumab in all-comers (A), CXCL13-high (B), and CXCL13-low patient subsets (C), and for CXCL13 versus achievement of an ACR50 response at week 24 for tocilizumab in all-comers (D), sICAM1-high (E) and sICAM1-low patient subsets (F). Biomarker high and low designations were made using their respective medians as the cutoff. Area under the ROC curve (AUC) is indicated for each plot.
Format: ZIP Size: 387KB Download file
Dennis et al. Arthritis Research & Therapy 2014 16:R90 doi:10.1186/ar4555